Effect of Hijamat Bil Shurt on Primary Hypertension —An open Randomized Control Study

<p>Hypertension is a disorder of circulatory regulation characterized by persistent, non physiologic elevation of systemic blood pressure. It is the leading cause of death in the world. In India and its surrounding countries. awareness level of this disease is &lt; 45%, out of them only hatf of the sufferers are on treatment, with poor adequacy of control of blood pressure. 90 to 95% of hypertensive patients suffer from Primary hypertension. in which a single reversible cause of the elevated blood pressure cannot be identified. The dinical features of target organ damage due to Hypertension correspond with the clinical features of Imtila. Hgamat Bil Shurt is a prescribed by Unani physicians to treat the Imtlja. To evaluate the efficacy of Hijamat Bil Shurt in the management of primary hypertension, an open randomized standard control trial conducted in 50 cases. After obtaining informed consent 30 patients of test group were subjected to the test procedure (Hijamat Bil Shurt ) once only, and 20 patients of control group were treated with standard control 25 mg of Atenolot once daily. both groups were followed up for 60 days. Al the cases were assessed for subjective and objective parameters. The results were analyzed statistically. The test group exhibited statistically significant reduction in SBP at P&lt;0.05, P&lt;0.001with respect to 0 day of test and p&lt;0.05, P&lt;0.01 with respect to O day of control and DBP at P&lt;0.001 , p&lt;0.001 with respect to 0 day of test and P&lt;0.05 with respect to 0 day of control. No adverse effects were observed during and after trial.</p>